HF2624

HF2624 (Legislative Session 94 (2025-2026))

Provisions in the prescription monitoring program changed.

Related bill: SF2806

AI Generated Summary

Purpose of the Bill:

This legislative bill aims to amend the Minnesota statutes related to the Prescription Monitoring Program (PMP). The bill seeks to enhance the management and regulation of controlled substances by updating the electronic reporting system and clarifying data access policies. It strives to better monitor prescription use, improve patient safety, and ensure compliance while respecting patient privacy.

Main Provisions:

Updated Definitions: Redefines terms related to controlled substances reporting, including specific drugs such as butalbital, gabapentin, and FDA-approved opioid overdose reversal agents.
Electronic Reporting System: Clarifies the role of the Board in establishing an electronic system for reporting controlled substances dispensation data. It allows for contractual technical assistance to support the system's design and operation.
Data Submission and Reporting Requirements: Establishes specific data points that dispensers must report, such as prescriber and patient details, to ensure comprehensive monitoring. Certain exemptions apply for specific patient scenarios, like those receiving short-term prescriptions.
Access and Use of Data: Specifies permissible users of the PMP, including prescribers, dispensers, healthcare professionals, and law enforcement with a valid warrant, ensuring they utilize the data responsibly and securely.
Patient Rights: Patients have the right to access their own data records in the monitoring program to see who has accessed their information.
Security and Privacy: Establishes robust security protocols, including encryption and audit logs, to protect personally identifiable information and ensure proper use.

Significant Changes:

Expanded Monitoring: Includes additional substances under the monitoring scope and details the responsibility of different healthcare and regulatory bodies in accessing and using controlled substances data.
Increased Privacy Measures: Enhancements to data privacy and security measures, implementing detailed auditing procedures for ensuring compliance with access rules, and limiting unauthorized data access.
Enhanced Accountability: Imposes stricter accountability for those who misuse access privileges or fail to report data accurately.

Relevant Terms:

Prescription Monitoring Program (PMP)
Controlled Reportable Substances
Minnesota State Board of Pharmacy
Prescription Data
Opiates and Opioid Antagonists
Electronic Reporting System
Health-related Licensing Board
Prescription Drug Abuse
Data Privacy and Security

Bill text versions

Introduction PDF file

Actions

Date	Chamber	Where	Type	Name	Committee Name
March 19, 2025	House	Floor	Action	Introduction and first reading, referred to	Health Finance and Policy

Citations

[
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Clarifies the definition of 'dispense or dispensing' in the context of controlled substances.",
      "modified": [
        "Reiterates that dispensing does not include direct administering by healthcare professionals."
      ]
    },
    "citation": "151.1",
    "subdivision": "subdivision 30"
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Lists substances considered as 'controlled reportable substances'.",
      "modified": [
        "Expands the substances list to include approved opioid antagonists."
      ]
    },
    "citation": "152.02",
    "subdivision": "subdivisions 3 to 6"
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Defines additional controlled substances as determined by the Minnesota Board of Pharmacy.",
      "modified": [
        "Details on specific substances like butalbital and gabapentin."
      ]
    },
    "citation": "152.02",
    "subdivision": "subdivisions 7, 8, and 12"
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Exempts certain prescriptions dispensed by veterinarians.",
      "modified": [
        "Clarification on veterinary prescription handling."
      ]
    },
    "citation": "156.18",
    "subdivision": ""
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Defines privacy related to data on individuals.",
      "modified": [
        "Emphasizes privacy protections for data within prescription monitoring."
      ]
    },
    "citation": "13.02",
    "subdivision": "subdivision 12"
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Lists health-related licensing boards and their permissions.",
      "modified": [
        "Access provisions to prescription monitoring data."
      ]
    },
    "citation": "214.01",
    "subdivision": "subdivision 2"
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Refers to health care directives.",
      "modified": [
        "Clarifies who can access information under these directives."
      ]
    },
    "citation": "145C",
    "subdivision": ""
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Relates to the health professionals services program.",
      "modified": [
        "Information access for those monitored by the program."
      ]
    },
    "citation": "214.31",
    "subdivision": ""
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Details data sharing conditions between health boards.",
      "modified": [
        "Restrictions and permissions related to health data."
      ]
    },
    "citation": "214.33",
    "subdivision": "subdivision 3"
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Defines criminal activities related to controlled reportable substances.",
      "modified": [
        "Clarification on illegal activities."
      ]
    },
    "citation": "152.025",
    "subdivision": ""
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Establishes opioid prescribing improvement program guidelines.",
      "modified": [
        "Provides framework for prescribing protocols."
      ]
    },
    "citation": "256B.0638",
    "subdivision": ""
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Details contract requirements for data usage.",
      "modified": [
        "Ensures contracted vendors comply with data privacy."
      ]
    },
    "citation": "13.05",
    "subdivision": "subdivision 6"
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Relates to licensing of opioid treatment programs.",
      "modified": [
        "Requirements for monitoring prescriptions in treatment programs."
      ]
    },
    "citation": "245A",
    "subdivision": ""
  },
  {
    "analysis": {
      "added": [
        ""
      ],
      "removed": [
        ""
      ],
      "summary": "Federal regulation related to confidentiality of alcohol and drug abuse patient records.",
      "modified": [
        "Impacts on data sharing for opioid treatment."
      ]
    },
    "citation": "2.34",
    "subdivision": "paragraph c"
  }
]